vs
Side-by-side financial comparison of Dianthus Therapeutics, Inc. (DNTH) and LQR House Inc. (YHC). Click either name above to swap in a different company.
LQR House Inc. is the larger business by last-quarter revenue ($299.7K vs $284.0K, roughly 1.1× Dianthus Therapeutics, Inc.). LQR House Inc. runs the higher net margin — -1368.7% vs -22687.3%, a 21318.6% gap on every dollar of revenue. On growth, LQR House Inc. posted the faster year-over-year revenue change (-64.2% vs -78.6%). Over the past eight quarters, LQR House Inc.'s revenue compounded faster (-21.1% CAGR vs -44.6%).
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
LQR House Inc. is a US-based alcohol beverage e-commerce and distribution company. It offers a broad portfolio of spirits, wine, and beer, operating two core segments: direct-to-consumer retail for individuals and wholesale distribution for business clients across the United States.
DNTH vs YHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0K | $299.7K |
| Net Profit | $-64.4M | $-4.1M |
| Gross Margin | — | 17.8% |
| Operating Margin | -24486.3% | -1000.3% |
| Net Margin | -22687.3% | -1368.7% |
| Revenue YoY | -78.6% | -64.2% |
| Net Profit YoY | -126.6% | 72.2% |
| EPS (diluted) | $-1.53 | $2.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0K | $299.7K | ||
| Q3 25 | $396.0K | $337.3K | ||
| Q2 25 | — | $498.5K | ||
| Q1 25 | $1.2M | $429.3K | ||
| Q4 24 | $1.3M | $838.2K | ||
| Q3 24 | $2.2M | $624.5K | ||
| Q2 24 | $1.9M | $557.9K | ||
| Q1 24 | $874.0K | $481.1K |
| Q4 25 | $-64.4M | $-4.1M | ||
| Q3 25 | $-36.8M | $-16.8M | ||
| Q2 25 | — | $-2.2M | ||
| Q1 25 | $-29.5M | $-2.4M | ||
| Q4 24 | $-28.4M | $-14.8M | ||
| Q3 24 | $-25.2M | $-3.4M | ||
| Q2 24 | $-17.6M | $-2.2M | ||
| Q1 24 | $-13.7M | $-2.4M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 17.0% | ||
| Q1 25 | — | 7.0% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -9.9% | ||
| Q2 24 | — | -27.3% | ||
| Q1 24 | — | -16.5% |
| Q4 25 | -24486.3% | -1000.3% | ||
| Q3 25 | -10173.7% | -1134.8% | ||
| Q2 25 | — | -442.1% | ||
| Q1 25 | -2852.7% | -559.0% | ||
| Q4 24 | -2406.9% | -1221.3% | ||
| Q3 24 | -1376.6% | -561.1% | ||
| Q2 24 | -1191.8% | -407.7% | ||
| Q1 24 | -2041.6% | -513.9% |
| Q4 25 | -22687.3% | -1368.7% | ||
| Q3 25 | -9284.1% | -4989.5% | ||
| Q2 25 | — | -441.8% | ||
| Q1 25 | -2537.5% | -556.6% | ||
| Q4 24 | -2144.8% | -1760.2% | ||
| Q3 24 | -1159.0% | -538.6% | ||
| Q2 24 | -945.1% | -396.0% | ||
| Q1 24 | -1573.0% | -504.6% |
| Q4 25 | $-1.53 | $2.94 | ||
| Q3 25 | $-0.97 | $-1.50 | ||
| Q2 25 | — | $-1.10 | ||
| Q1 25 | $-0.82 | $-3.85 | ||
| Q4 24 | $-0.76 | $-88.71 | ||
| Q3 24 | $-0.74 | $-21.84 | ||
| Q2 24 | $-0.51 | $-15.49 | ||
| Q1 24 | $-0.54 | $-18.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $404.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $493.4M | $29.3M |
| Total Assets | $530.9M | $31.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $404.3M | — | ||
| Q3 25 | $402.6M | $10.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | $263.2M | — | ||
| Q4 24 | $275.2M | $5.4M | ||
| Q3 24 | $281.1M | $3.7M | ||
| Q2 24 | $360.7M | $4.6M | ||
| Q1 24 | $377.0M | $4.0M |
| Q4 25 | $493.4M | $29.3M | ||
| Q3 25 | $546.5M | $27.4M | ||
| Q2 25 | — | $12.2M | ||
| Q1 25 | $328.6M | $7.3M | ||
| Q4 24 | $352.5M | $-518.0K | ||
| Q3 24 | $337.9M | $9.1M | ||
| Q2 24 | $358.2M | $11.7M | ||
| Q1 24 | $372.7M | $12.4M |
| Q4 25 | $530.9M | $31.2M | ||
| Q3 25 | $577.4M | $35.0M | ||
| Q2 25 | — | $14.4M | ||
| Q1 25 | $348.6M | $9.6M | ||
| Q4 24 | $374.0M | $6.9M | ||
| Q3 24 | $354.2M | $9.8M | ||
| Q2 24 | $369.0M | $12.2M | ||
| Q1 24 | $382.5M | $12.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.0M | $-14.3M |
| Free Cash FlowOCF − Capex | $-47.1M | — |
| FCF MarginFCF / Revenue | -16591.9% | — |
| Capex IntensityCapex / Revenue | 48.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-132.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.0M | $-14.3M | ||
| Q3 25 | $-30.6M | $-11.3M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | $-27.6M | $-6.6M | ||
| Q4 24 | $-27.4M | $-3.1M | ||
| Q3 24 | $-21.3M | $-1.0M | ||
| Q2 24 | $-14.5M | $-1.2M | ||
| Q1 24 | $-14.9M | $-1.4M |
| Q4 25 | $-47.1M | — | ||
| Q3 25 | $-30.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-27.5M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-14.5M | — | ||
| Q1 24 | $-15.0M | $-1.4M |
| Q4 25 | -16591.9% | — | ||
| Q3 25 | -7717.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -2377.8% | — | ||
| Q4 24 | -2072.0% | — | ||
| Q3 24 | -980.3% | — | ||
| Q2 24 | -780.7% | — | ||
| Q1 24 | -1713.2% | -287.7% |
| Q4 25 | 48.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 3.7% | 2.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
